Related Experiment Video
Updated: May 15, 2026
10:02
Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
Published on: December 19, 2025
Towards pancreatic cancer diagnosis using EIS biochips
Maria Serena Chiriacò1, Elisabetta Primiceri, Anna Grazia Monteduro
1NNL Istituto Nanoscienze - CNR and Dipartimento di Matematica e Fisica Ennio De Giorgi, Scuola Superiore ISUFI, Università del Salento, Via per Arnesano, I-73100 Lecce, Italy. serena.chiriaco@unisalento.it
Lab on a Chip
|January 5, 2013
Summary
This study presents a novel microfluidic biosensor for detecting pancreatic cancer (PDAC). The platform identifies autoantibodies against phosphorylated α-enolase (ENOA), improving early and accurate PDAC diagnosis.
Area of Science:
- Biomedical Engineering
- Oncology
- Analytical Chemistry
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with poor survival rates.
- Current diagnostic markers for PDAC lack specificity, leading to late and imprecise diagnoses.
- Autoantibodies against phosphorylated α-enolase (ENOA) show potential as supplementary PDAC biomarkers.
Purpose of the Study:
- To develop and validate a microfluidic electrochemical impedance spectroscopy (EIS) biosensor for PDAC diagnosis.
- To assess the utility of detecting autoantibodies against phosphorylated ENOA peptides for PDAC detection.
- To compare the performance of the developed biosensor with traditional diagnostic methods.
Main Methods:
- Fabrication of a microfluidic platform with integrated EIS biosensors.
- Immobilization of phosphorylated ENOA peptides onto electrode surfaces for antibody capture.
- Detection of serum autoantibodies from PDAC patients using EIS.
- Validation of results against ELISA and Western blot techniques.
Main Results:
- The EIS biosensor successfully detected specific autoantibodies in PDAC patients' sera.
- Phosphorylation of ENOA peptides significantly influenced antibody recognition.
- The developed biochip demonstrated higher sensitivity and specificity compared to traditional methods.
- EIS measurements were faster, more reproducible, and label-free.
Conclusions:
- The microfluidic EIS biosensor is a promising tool for sensitive, specific, and rapid PDAC diagnosis.
- Detecting autoantibodies against phosphorylated ENOA offers a valuable approach to improve PDAC detection.
- This label-free, cost-effective technology enhances diagnostic capabilities for pancreatic cancer.
